Study of the Effect of VSL#3 on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs VSL 3 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 19 May 2016 Biomarkers information updated
- 25 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.